Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV–hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study

Abstract

Background

The aim of this study was to assess the effect of insulin resistance (IR) on the response to hepatitis C virus (HCV) therapy in HIV-HCV-coinfected patients.

Methods

A total of 238 HIV-HCV-coinfected patients (74% male, mean ±sd age 40 ±5 years, mean alcohol intake <50 g/day and 38% HCV genotype 2 or 3), treated by standard or pegylated interferon-α2b plus ribavirin during 48 weeks were studied. Liver biopsies were assessed before treatment. Patients were considered to have IR when the homeostasis model assessment of IR (HOMA-IR) was ≥2.5. Multiple logistic regression with stepwise selection was used to estimate independent factors associated with sustained virological response (SVR).

Results

IR was present in 32% and significant liver fibrosis (Metavir≥F2) in 74% of patients. Patients with SVR (96/238 [40%]) were more likely to be infected with HCV genotype 2 or 3 (54% versus 27%; P<0.0001), and had more severe liver fibrosis (≥F3; 45% versus 30%; P=0.03). By multivariate analysis, a HOMA-IR>2.5 had a negative effect on the SVR (odds ratio 0.49 [95% confdence interval 0.26-0.92]; P=0.05).

Conclusions

A high HOMA-IR level is frequently found in HIV-HCV-coinfected patients and is associated with a reduced SVR rate. Improving insulin sensitivity might be a useful adjunct to HCV therapy in HIV-HCV-coinfected patients.

References

Camma

, Bruno

, Di Marco

Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C.

Hepatology 2006; 43: 64–71.

Mirandola

, Realdon

, Iqbal

Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis.

Gastroenterology 2006; 130: 1661–1669.

Okuda

, Li

, Beard

M.R.

Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein.

Gastroenterology 2002; 122: 366–375.

Romero-Gomez

, Del Mar Viloria

, Andrade

R.J.

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

Gastroenterology 2005; 128: 636–641.

Conjeevaram

H.S.

, Kleiner

D.E.

, Everhart

J.E.

Race, insulin resistance and hepatic steatosis in chronic hepatitis C.

Hepatology 2007; 45: 80–87.

Sulkowski

M.S.

, Thomas

D.L.

Hepatitis C in the HIV-infected person.

Ann Intern Med 2003; 138: 197–207.

Sherman

, Roustrer

, Chung

, Rajicic

Hepatitis C: prevalence in HIV-infected patients across sectional analysis of the US ACTG.

Antivir Ther 2000; 5 Suppl 1: 64–65.

Benhamou

, Bochet

, Di Martino

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group.

Hepatology 1999; 30: 1054–1058.

Puoti

, Bonacini

, Spinetti

Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus.

J Infect Dis 2001; 183: 134–137.

10.

de Torres

, Poynard

Risk factors for liver fibrosis progression in patients with chronic hepatitis C.

Ann Hepatol 2003; 2: 5–11.

11.

Kramer

J.R.

, Giordano

T.P.

, Souchek

, Richardson

, Hwang

L.Y.

, El-Serag

H.B.

The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in US veterans with hepatitis C.

Am J Gastroenterol 2005; 100: 56–63.

12.

Benhamou

, Di Martino

, Bochet

Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy.

Hepatology 2001; 34: 283–287.

13.

Sterling

R.K.

, Contos

M.J.

, Sanyal

A.J.

The clinical spectrum of hepatitis C virus in HIV coinfection.

J Acquir Immune Defic Syndr 2003; 32: 30–37.

14.

Martin-Carbonero

, Soriano

, Valencia

, Garcia-Samaniego

, Lopez

, Gonzalez-Lahoz

Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients.

AIDS Res Hum Retroviruses 2001; 17: 1467–1471.

15.

Puoti

, Spinetti

, Ghezzi

Mortality for liver disease in patients with HIV infection: a cohort study.

J Acquir Immune Defic Syndr 2000; 24: 211–217.

16.

Martin-Carbonero

, Benhamou

, Puoti

Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study.

Clin Infect Dis 2004; 38: 128–133.

17.

Cacoub

, Geffray

, Rosenthal

, Perronne

, Veyssier

, Raguin

Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997.

Clin Infect Dis 2001; 32: 1207–1214.

18.

Bica

, McGovern

, Dhar

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection.

Clin Infect Dis 2001; 32: 492–497.

19.

Selik

R.M.

, Byers

R.H.

Jr. , Dworkin

M.S.

Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999.

J Acquir Immune Defic Syndr 2002; 29: 378–387.

20.

Rosenthal

, Poiree

, Pradier

Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study).

AIDS 2003; 17: 1803–1809.

21.

Rosenthal

, Pialoux

, Bernard

Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study).

J Viral Hepat 2007; 14: 183–188.

22.

Chung

R.T.

, Andersen

, Volberding

Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.

N Engl J Med 2004; 351: 451–459.

23.

Torriani

F.J.

, Rodriguez-Torres

, Rockstroh

J.K.

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

N Engl J Med 2004; 351: 438–450.

24.

Carrat

, Bani-Sadr

, Pol

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.

JAMA 2004; 292: 2839–2848.

25.

Laguno

, Murillas

, Blanco

J.L.

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.

AIDS 2004; 18: F27–F36.

26.

The French METAVIR Cooperative Study Group.

Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C.

Hepatology 1994; 20: 15–20.

27.

Matthews

D.R.

, Hosker

J.P.

, Rudenski

A.S.

, Naylor

B.A.

, Treacher

D.F.

, Turner

R.C.

Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Diabetologia 1985; 28: 412–419.

28.

Ozdemir

, Yalinbas

, Selamet

The effect of hepatitis C virus infection on insulin resistance in chronic haemodialysis patients.

Yonsei Med J 2007; 48: 274–280.

29.

Masuo

, Katsuya

, Ogihara

, Tuck

M.L.

Acute hyperinsulinemia reduces plasma leptin levels in insulin-sensitive Japanese men.

Am J Hypertens 2005; 18: 235–243.

30.

Manns

M.P.

, McHutchison

J.G.

, Gordon

S.C.

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Lancet 2001; 358: 958–965.

31.

Bani-Sadr

, Goderel

, Morand

High hepatitis C virus viral load in HIV/hepatitis C virus-co-infected patients: a different influence of protease inhibitor and non-protease inhibitor-based HAART?

AIDS 2007; 21: 1645–1648.

32.

Lok

A.S.

, Everhart

J.E.

, Chung

R.T.

Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial.

Clin Gastroenterol Hepatol 2007; 5: 245–254.

33.

Dai

C.Y.

, Huang

J.F.

, Hsieh

M.Y.

Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients.

J Hepatol 2009; 50: 712–718.

34.

Harrison

S.A.

Steatosis and chronic hepatitis C infection: mechanisms and significance.

Clin Gastroenterol Hepatol 2005; 3: S92–S96.

35.

Ryan

, Resino

, Miralles

Insulin resistance impairs sustained virologic response to interferon plus ribavirin in HIV/HCV co-infected patients. 16th Conference on Retroviruses and Opportunistic Infections. 8–11 February 2009, Montreal, QC, Canada. Abstract Q-162.

36.

Merchante

, de los Santos-Gil

, Merino

Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients.

J Hepatol 2009; 50: 684–692.

37.

Nasta

, Gatti

, Puoti

Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a.

AIDS 2008; 22: 857–861.

38.

Ryan

, Berenguer

, Michelaud

Insulin resistance is associated with advanced liver fibrosis and high body mass index in HIV/HCV-coinfected patients.

J Acquir Immune Defic Syndr 2009; 50: 109–110.

39.

Bugianesi

, Marchesini

, Gentilcore

Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: role of insulin resistance and hepatic steatosis.

Hepatology 2006; 44: 1648–1655.

40.

Chitturi

, Abeygunasekera

, Farrell

G.C.

NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome.

Hepatology 2002; 35: 373–379.

41.

Moucari

, Asselah

, Cazals-Hatem

Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis.

Gastroenterology 2008; 134: 416–423.

42.

Poustchi

, Negro

, Hui

Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3.

J Hepatol 2008; 48: 28–34.

43.

Bani-Sadr

, Carrat

, Bedossa

Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors.

AIDS 2006; 20: 525–531.

44.

Mira

J.A.

, Torre-Cisneros

, Merino

Efficacy of pegylated intereron plus ribavirin in HIV/HCV coinfection outside of well circumscribed clinical trials: the Andalusian multicenter study. 13th Conference on Retroviruses and Opportunistic Infections, 5–8 February 2006, Denver, CO, USA. Abstract 861.

45.

D'Souza

, Sabin

C.A.

, Foster

G.R.

Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy.

Am J Gastroenterol 2005; 100: 1509–1515.

46.

Camma

, Petta

Insulin resistance in HCV mono-infected and in HIV/HCV co-infected patients: looking to the future.

J Hepatol 2009; 50: 648–651.

47.

Shire

, Rao

, Andersen

Improving non-invasive discrimination of fibrosis in HIV/HCV-co-infected patients. 14th Conference on Retroviruses and Opportunistic Infections. 25–28 February 2007, Los Angeles, CA, USA. Abstract 914.

48.

Overbeck

, Genne

, Golay

, Negro

Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin.

J Hepatol 2008; 49: 295–298.

49.

Basu

, Shah

, Basu

Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.

Diabetes 2008; 57: 24–31.

50.

Shaw

R.J.

, Lamia

K.A.

, Vasquez

The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin.

Science 2005; 310: 1642–1646.

51.

Elgouhari

H.M.

, Cesario

, Lopez

, Zein

Pioglitazone improves early virologic kinectic response to PEG IFN/RBV combination therapy in hepatitis C genotype 1 naive patients.

Hepatology 2008; 48: 383A.

52.

Romero Gomez

, Diago

, Andrade

Metformin with peginterferon alfa-2a and ribavirin in the treatment of naive genotype 1 chronic hepatitis C patients with insulin resistance (TRIC-1): final results of a randomized and double-blinded trial.

Hepatology 2008; 48: 380A.